Ideas
Mag7 capex fuels semiconductor outperformance
Mag7 companies are selling equity and raising debt to fund massive capex for AI data centers, which directly benefits the semiconductor companies they buy from; Intel just signed a deal with Apple, and the entire semiconductor complex is continuously rampaging higher. This dynamic will persist through the summer.
Goldilocks period drives US equities higher
Buy SPY as broad US equities enter a Goldilocks summer setup: markets shrugged off hawkish Fed/rate-hike pricing, Iran/oil fears, and earnings worries, and slowing summer news flow could support a rally into August.
HOOD growth reaccelerates, layoffs are bullish
Robinhood (HOOD) is performing very well: platform assets up 50% YoY to ~$400B, gold subscribers up 36% in Q1, and they are rolling out crypto trading to all users. The recent 10% workforce cut is bullish because the savings get reallocated to growth areas and share buybacks. HOOD is a better play than Hyperliquid, which is being held back by the crypto complex.
Avoid emerging markets, US exceptionalism dominates
The thesis that emerging markets would dominate in 2026 has completely failed; only Korea performed because of its semiconductor industry, while true AI-driven innovation remains concentrated in the United States. This makes EM an unattractive destination for capital.
Strong dollar hits gold, Bitcoin, commodities
US exceptionalism is strengthening the dollar, which is unambiguously negative for gold, Bitcoin, and commodities in general. Additionally, Michael Saylor's STRC problems and the structural unwind in Bitcoin reinforce that one should not be touching Bitcoin right now.
Iran flare-up risk spikes oil, hits equities
The Iran deal is a win for Iran and an untenable agreement that will likely lead to future conflict. With the administration focused on keeping the situation calm through the midterms, a flare-up could occur after the midterms, causing a spike in oil prices and a tumble in equity markets. This is a setup to monitor closely.
AI biotech megatrend, buy ARKG
AI is finally being applied to physical products and drug discovery, not just software. The FDA under RFK is becoming much more accommodating, as shown by the full U-turn on gene therapy. Avi bought ARKG (ARK Genomic Revolution ETF) with 3% of his portfolio and plans to increase exposure to genomics and biotech as this megatrend plays out.
Monitor Insilico Medicine
Insilico Medicine is a pure-play AI drug discovery company based in Boston but trading on the Hong Kong stock exchange. With AI revolutionizing biotech and the FDA becoming more lenient, this company is a compelling candidate to watch while he conducts deeper research.
Nuclear renaissance, buy uranium ETF URA
A nuclear revolution is coming in the US over the next 3–5 years driven by the Trump administration and new efficient reactor companies. While uranium commodity prices may not surge because supply can be ramped, the companies and ETFs will see massive revenue growth. URA is well off its highs and could deliver a 3–5x return.
This 1000x Podcast video, published June 19, 2026,
features Avi Felman
discussing INTC, MU, SNDK, SPY, HOOD, EEM, GLD, DBC, BTC, WTI, ARKG, Insilico Medicine, URA.
9 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Avi Felman
· Tickers:
INTC,
MU,
SNDK,
SPY,
HOOD,
EEM,
GLD,
DBC,
BTC,
WTI,
ARKG,
Insilico Medicine,
URA